Wells Fargo & Company Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its price target dropped by investment analysts at Wells Fargo & Company from $45.00 to $38.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 126.73% from the stock’s previous close.

Several other brokerages have also recently commented on SRPT. Guggenheim dropped their target price on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Royal Bank Of Canada lifted their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Wall Street Zen cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday, January 27th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $33.56.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $16.76 on Friday. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $108.48. The stock has a market capitalization of $1.76 billion, a P/E ratio of -1.99, a P/E/G ratio of 0.42 and a beta of 0.39. The business has a 50-day moving average price of $20.43 and a two-hundred day moving average price of $20.22.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The business had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative return on equity of 49.42% and a negative net margin of 38.34%.The firm’s quarterly revenue was down 32.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 EPS. Equities analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the transaction, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. This represents a 6.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 7.60% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently made changes to their positions in SRPT. Kestra Advisory Services LLC bought a new position in Sarepta Therapeutics in the fourth quarter valued at $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth about $25,000. Ancora Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares in the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $33,000. Finally, Allworth Financial LP raised its holdings in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.